NeuroVive Pharmaceutical AB Rentabilidad sobre recursos propios

¿Qué es el Rentabilidad sobre recursos propios de NeuroVive Pharmaceutical AB?

El Rentabilidad sobre recursos propios de NeuroVive Pharmaceutical AB es -69.63%

¿Cuál es la definición de Rentabilidad sobre recursos propios?



El rendimiento del capital es una medida de la rentabilidad de una empresa en relación con el valor contable del capital contable. Se calcula dividiendo los ingresos netos del año fiscal por el capital contable total.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Rentabilidad sobre recursos propios de compañías en Sector Miscellaneous en LSE en comparadas con NeuroVive Pharmaceutical AB

¿Qué hace NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Empresas con rentabilidad sobre recursos propios similar a NeuroVive Pharmaceutical AB